Zionexa, a new company specialized in R&D and commercialization of innovative molecular imaging solutions in oncology

Paris (France), May 16th, 2018 – Zionexa, a new radiopharmaceutical company, has been created to develop and commercialize innovative molecular imaging diagnostic companions (CDx) for targeted therapies in oncology that can improve patients’ pathway within the framework of new personalized diagnostic approaches. 

A targeted and innovative diagnostic approach in oncology 

Zionexa, owned by Denos, has taken over the development of the most innovative molecules coming from Cyclopharma’s pipeline. The objective is to drive the development, commercialization, and access to American and international markets, beginning with Estrotep. EstroTep is a new biomarker, (currently approved for use in France) which can be used as an additional tool in patient care for metastatic breast cancer. 

Zionexa’s pipeline includes other innovative CDx molecules including a molecule targeting EGFR gene mutations in lung cancer, IMAKinib, co-developed with Oncodesign. 

An expert and international team 

Zionexa will rely on its expert and international team to meet its goals, formed by key former members of Cyclopharma’s management team: Bernard Landès – CEO, Peter Webner – CEO US, Jean-Bernard Deloye – Market Access Director, Yann Bouvet – R&D Director, Jérôme Francillard – CFO. 

Commenting this announcement, Olivier Carli, President of Denos, says: “Zionexa is a very promising company, thanks to its pipeline of innovative molecules and its team of experts actively involved in participating in the future of molecular imaging.” 

Bernard Landès, Zionexa CEO, pursues: “I am really confident about the future development of Zionexa and I am really pleased to be supported by a team of great experts for this new project, because there is a real need to discover new molecular imaging CDx in oncology, that can improve patients’ quality of life. We are going to continue with Zionexa what we initiated in 2013 with Cyclopharma, in France and especially in the United-States, where we already have established a regulatory team for EstroTep, specialized in breast cancer diagnosis.” 

Distribution of Metastases per Patient